CureVac

CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid, or mRNA. The company was founded in 2000 and had its initial public offering in August 2020. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and Covid vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.

Virus,Sample,For,H5n1,(avian,Influenza,Virus),Test,,Avian,Influenza

Large Cap

News

Health Care

General

CVAC

MRNA

NVAX

A Nevada dairy worker who initially tested positive for bird flu is currently experiencing mild symptoms, including &#34;pink eye.&#34;

Deadly Bird Flu Strain Detected In Nevada Man: 4 Stocks To Watch (CORRECTED)

Bird flu, chickens, vet

Government

Politics

As the bird flu virus continues to spread through the United States, the Trump administration on Tuesday ordered all communications from the Centers for Disease Control and Prevention to stop. 

Trump Administration Halts All Communications From The Centers For Disease Control As Bird Flu Spreads

A,Test,Tube,With,A,Blood,Test,For,H5n1,Avian

Biotech

Equities

Markets

CALM

According to the latest data from the Centers for Disease Control, the current bird flu outbreak has caused 67 human cases of bird flu in the U.S. and one death associated with the virus.

Bird Flu Update: First Commercial Case In Georgia, Moderna Receives $590 Million To Develop Vaccine

CureVac NV

Earnings

Press Releases

CureVac Announces Financial Results for the Second Quarter and First Half of 2024 and Provides Business Update

CureVac to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 Congress

CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza  mRNA Vaccine Program

CureVac's CVGBM Cancer Vaccine Induces Promising Immune Responses in Phase 1 Study in Glioblastoma Presented at the ESMO 2024 Congress

Events

CureVac to Present at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

CureVac to Present at the 12th International mRNA Health Conference

Management

CureVac Strengthens Leadership Team with Appointment of Seasoned Industry Executive Axel Sven Malkomes as Chief Financial Officer

CureVac to Report Third Quarter and First Nine Months 2024 Financial Results and Business Update on November 12, 2024

CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update

CureVac Earns Repeat Recognition by LexisNexis(R) as One of the World's Top Innovators

JMP Securities

Leerink Partners

B of A Securities

SVB Securities

Comments

CureVac

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga